ASCO 2025 Conference Review focus on Breast Cancer

In this edition:

DESTINY-Breast09: first-line T-DXd + pertuzumab vs. THP in HER2+ advanced/metastatic breast cancer
MA.40/FINER: second-line fulvestrant + ipatasertib in advanced HER2-/ER+ breast cancer
SERENA-6: camizestrant + CDK4/6i at emergence of ESR1 mutations with first-line aromatase inhibitor + CDK4/6i inHR+/HER2- advanced breast cancer
neoCARHP: de-escalated neoadjuvant taxane, trastuzumab & pertuzumab ± carboplatin in HER2+ early breast cancer
Real-world outcomes of rechallenge after T-DXd-related ILD
OASIS 4: elinzanetant for vasomotor symptoms with adjuvant endocrine therapy
TEXT/SOFT: final 15-year results
NATALEE: efficacy of ribociclib + nonsteroidal aromatase inhibitor by age/menopausal status
ASCENT-04: first-line Sacituzumab govitecan + pembrolizumab in PD-L1- positive advanced TNBC
VERITAC-2: vepdegestrant (PROTAC ER degrader) in ER+/HER- advanced breast cancer